Faricimab
Vabysmo (faricimab) is a prescription injectable solution manufactured by Genentech, Inc., administered via intravitreal injection (into the eye) for treating certain retinal conditions. It contains faricimab at 6 mg per 0.05 mL dose. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[ "009:10" ] |
| contactPoint |
{ "fn": "Division of Drug Information", "@type": "vcard:Contact", "hasEmail": "mailto:druginfo@fda.hhs.gov" } |
| description | Vabysmo (faricimab) is a prescription injectable solution manufactured by Genentech, Inc., administered via intravitreal injection (into the eye) for treating certain retinal conditions. It contains faricimab at 6 mg per 0.05 mL dose. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[ { "@type": "dcat:Distribution", "title": "Faricimab", "mediaType": "text/html", "description": " Access the FDA dataset for Faricimab — ANDA 761235 submitted by Mylan Institutional LLC ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761235" } ] |
| identifier | ANDA761235 |
| issued | 2016-09-16 |
| keyword |
[ "drug", "drug-safety", "fda", "prescription-drugs", "public-health" ] |
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[ "009:002" ] |
| publisher |
{ "name": "U.S. Food and Drug Administration", "@type": "org:Organization" } |
| theme |
[ "FDA" ] |
| title | Faricimab |
